Ernexa Therapeutics Formally Executes 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

Ernexa Therapeutics Inc. filed a certificate of amendment to effect a 1-for-25 reverse stock split, effective May 4, 2026, a move aimed at regaining compliance with Nasdaq listing requirements.

check_boxKey Events

• Reverse Stock Split Effective

  Ernexa Therapeutics Inc. filed a certificate of amendment on May 1, 2026, to effect a 1-for-25 reverse stock split, which became effective at market open on May 4, 2026.

• Nasdaq Compliance Measure

  The reverse stock split is a critical step to help the company regain compliance with Nasdaq's minimum bid price requirement, following previous announcements regarding delisting risk.

• New CUSIP Number Issued

  Following the reverse stock split, the common stock began trading under a new CUSIP number, 114082407.

auto_awesomeAnalysis

This 8-K filing formalizes the previously announced 1-for-25 reverse stock split, which became effective at market open on May 4, 2026. The reverse split is a critical measure for Ernexa Therapeutics to regain compliance with Nasdaq's minimum bid price requirement, as the company has been at high risk of delisting and faces going concern doubts. While necessary for continued listing, this action does not address the underlying operational or financial challenges. Investors should monitor whether this compliance measure is sufficient to stabilize the company's market position and if any fundamental improvements follow.